Exagen (XGN) Competitors $3.99 +0.93 (+30.39%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XGN vs. SERA, LFMD, BDSX, QIPT, CORBF, EUDA, PIII, BNR, ENZ, and TOIShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Sera Prognostics (SERA), LifeMD (LFMD), Biodesix (BDSX), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), EUDA Health (EUDA), P3 Health Partners (PIII), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry. Exagen vs. Sera Prognostics LifeMD Biodesix Quipt Home Medical Global Cord Blood EUDA Health P3 Health Partners Burning Rock Biotech Enzo Biochem Oncology Institute Exagen (NASDAQ:XGN) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment. Does the MarketBeat Community prefer XGN or SERA? Exagen received 13 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 57.50% of users gave Exagen an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformExagenOutperform Votes2357.50% Underperform Votes1742.50% Sera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Do institutionals and insiders hold more shares of XGN or SERA? 75.3% of Exagen shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 26.1% of Exagen shares are held by insiders. Comparatively, 15.8% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is XGN or SERA more profitable? Sera Prognostics has a net margin of 0.00% compared to Exagen's net margin of -30.36%. Sera Prognostics' return on equity of -51.73% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-30.36% -92.58% -33.74% Sera Prognostics N/A -51.73%-36.94% Which has higher earnings and valuation, XGN or SERA? Exagen has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$52.55M1.34-$23.69M-$0.94-4.24Sera Prognostics$310K699.37-$36.24M-$0.99-6.48 Which has more risk and volatility, XGN or SERA? Exagen has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Does the media refer more to XGN or SERA? In the previous week, Sera Prognostics had 16 more articles in the media than Exagen. MarketBeat recorded 18 mentions for Sera Prognostics and 2 mentions for Exagen. Exagen's average media sentiment score of 0.56 beat Sera Prognostics' score of 0.40 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate XGN or SERA? Exagen currently has a consensus price target of $7.50, indicating a potential upside of 87.97%. Given Exagen's higher probable upside, equities analysts clearly believe Exagen is more favorable than Sera Prognostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryExagen beats Sera Prognostics on 13 of the 17 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.38M$2.96B$5.21B$9.15BDividend YieldN/A16.02%5.13%4.03%P/E Ratio-4.2415.3488.0817.36Price / Sales1.34200.801,243.2778.03Price / CashN/A426.0143.7535.97Price / Book3.004.925.314.79Net Income-$23.69M-$33.85M$122.62M$225.00M7 Day Performance27.88%2.81%0.61%2.62%1 Month Performance-22.52%0.53%2.56%3.81%1 Year Performance101.52%15.34%25.79%20.10% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen4.7657 of 5 stars$3.99+30.4%$7.50+88.0%+101.5%$70.38M$52.55M-4.24220High Trading VolumeSERASera Prognostics0.6953 of 5 stars$6.33-8.7%N/A+7.0%$213.78M$94,000.00-6.39120LFMDLifeMD3.0552 of 5 stars$4.72-0.4%$11.14+136.1%-18.6%$204.43M$193.06M-7.38230BDSXBiodesix3.7648 of 5 stars$1.24-2.4%$3.06+146.8%-39.5%$180.38M$65.56M-3.18220Short Interest ↓QIPTQuipt Home Medical2.8098 of 5 stars$3.06+2.0%$6.25+104.2%-34.1%$131.86M$245.92M-27.82800News CoverageCORBFGlobal Cord BloodN/A$1.00flatN/A-19.2%$121.55M$196.12M0.001,200EUDAEUDA Health0.5876 of 5 stars$4.17-5.7%N/A+150.3%$102.70M$3.81M0.002Positive NewsPIIIP3 Health Partners2.3988 of 5 stars$0.21-0.6%$2.38+1,010.9%-83.0%$76.72M$1.48B-0.25500Positive NewsGap UpBNRBurning Rock Biotech2.095 of 5 stars$6.55-6.7%N/A-29.7%$67.10M$510.89M-2.181,390Short Interest ↓Positive NewsHigh Trading VolumeENZEnzo Biochem1.6871 of 5 stars$0.66-3.4%N/A-51.8%$34.32M$30.31M0.00520Analyst ForecastGap UpTOIOncology Institute2.4781 of 5 stars$0.31+3.3%$2.50+702.1%-74.3%$23.55M$324.24M-0.40660Gap Up Related Companies and Tools Related Companies SERA Alternatives LFMD Alternatives BDSX Alternatives QIPT Alternatives CORBF Alternatives EUDA Alternatives PIII Alternatives BNR Alternatives ENZ Alternatives TOI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XGN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XGN Stock Alerts